Home – Page 63 – The Cancer Letter

Issue 8 - Feb 24, 2017

TCL43-08 (2779 downloads)

GAO: Power morcellation is a unique case study in patient harm
Hundreds died over two decades as reporting requirements were ignored.
FDA’s passive reliance on self-reporting by hospitals and device manufacturers allowed harm caused by power morcellators to go unnoticed for over two decades—likely contributing to injury and deaths of hundreds of women, according to the U.S. Government Accountability Office.
Conversation with The Cancer Letter
Marcia Crosse: This “failure of the adverse event reporting system” should serve as a “wake up call”
Hundreds of women were injured or have died from upstaging of unsuspected uterine cancer by power morcellation because FDA didn’t know the actual risk of cancer in fibroids, and hospitals failed to report harm, according to the U.S. Government Accountability Office.
Moonshot funds are not a substitute for sustained NCI funding, Lowy warns as prospect of year-long continuing resolution looms
Moonshot appropriations are not a substitute for sustained increases in appropriations, NCI Acting Director Doug Lowy said at the meeting of the National Cancer Advisory Board Feb. 15.
“It’s critically important for us to be able to continue to meet our obligations in terms of inflation, but far more important to meet our obligations to the cancer research community,” Lowy said at the virtual meeting.
In Brief
- Cleveland Clinic opens new cancer center
- Jeffrey Patrick new director of Ohio State Drug Development Institute
Drugs and Targets
- FDA approves Revlimid as maintenance in multiple myeloma following transplant
- Zykadia receives a Priority Review for frontline use in ALK+ metastatic NSCLC
- FDA accepts Mylan’s BLA for biosimilar pegfilgrastim
- MIODx licenses immunotherapy technologies from UCSF
Funding Opportunities
DOD Lung Cancer Research Program publishes anticipated funding opportunities
Due to the current Continuing Resolution, the Fiscal Year 2017 Defense Appropriations bill has not been passed.
Although funds have not been appropriated for the Department of Defense Lung Cancer Research Program (LCRP), the LCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY17 funding opportunities.

Issue 7 - Feb 17, 2017

TCL43-07 (365 downloads)

Audit: Lynda Chin’s abandoned $62 million IBM Watson collaboration didn’t follow standard procedures
An audit of an abandoned mega-project run by IBM Watson and MD Anderson Cancer Center found that the Houston-based institution skirted the UT System’s procurement regulations as it spent $62.1 million on an ill-fated artificial intelligence system.
Is it research or run-of-the-mill IT?
The UT System report on the Oncology Expert Advisor Project raises questions about classification of development of artificial intelligence systems.
Are they research or are they IT systems?
Guest Editorial
The AACI Network Care Initiative
Many cancer center hospital systems are expanding their services across large geographic regions, while cancer care is consolidating around ever enlarging groups.
Over the next two years, as I serve as president of the Association of American Cancer Institutes, I will be leading an initiative to better define these networks and to develop methods of improving the quality of cancer care administered across individual cancer center networks, with better integration of treatment services, especially those now unique to our centers, into the community.
In Brief
- Salk scientist awarded $500K Swedish prize
- Prostate Cancer Foundation awards $8.6 million to eight teams
- U.S. Preventive Services Task Force appoints three new members
- BTG and Society of Interventional Oncology to explore role of minimally invasive therapies in immuno-oncology
- Perthera, Hope for Stomach Cancer to provide patient services
- RPRD Diagnostics, Children’s Minnesota to advance clinical pharmacogenomics
- Jeffery Kutok named chief scientific officer at Infinity
- CVS Health earns CEO Cancer Gold Standard accreditation
Drugs and Targets
- Amgen submits Supplemental Biologics License Application for Blincyto
- Pan-Canadian Pharmaceutical Alliance, BMS reach agreement on Opdivo
- Immunomedics enters into licensing agreement with Seattle Genetics for Sacituzumab Govitecan
Funding Opportunities
PCRP announces research awards application guidelines
The Department of Defense Prostate Cancer Research Program is pre-announcing the application process for its funding awards even though due to the current Continuing Resolution, the Fiscal Year 2017 Defense Appropriations bill has not been passed to allow investigators time to plan and develop ideas for submission to the anticipated FY17 funding opportunities.

Issue 6 - Feb 10, 2017

CL43-06 (312 downloads)

MMRF contributes largest disease-specific cancer genome dataset to NCI’s Genomic Data Commons
It took the Multiple Myeloma Research Foundation nearly a decade and over $40 million to create what the foundation describes as the largest disease-specific cancer genome dataset in existence.
The first installment of the dataset is now posted on NCI’s Genomic Data Commons, which places the information in the public domain, making it available to researchers.
Conversation with The Cancer Letter
Giusti: The $40 million multiple myeloma dataset will help predict risk and clinical response
The world’s biggest genomic database on multiple myeloma is being integrated into NCI’s Genomic Data Commons.
The data on the second most common blood cancer—with genomic information from about 1,400 patients—was compiled by the Multiple Myeloma Research Foundation through a genome mapping initiative and a $40 million network of clinical trials.
Steve Hahn takes over day to day operations at MD Anderson
Steve Hahn, a radiation oncologist, was named deputy to the president and chief operating officer at MD Anderson Cancer Center.
GAO report: FDA underestimated actual cancer risk, clearing 25 versions of morcellators in over 20 years
The Government Accountability Office Feb. 8 released an analysis of FDA’s failure to detect the health hazards of power morcellation, a once widely used procedure that has been shown to upstage uterine cancers.
In Brief
- International teams win £100 million in Cancer Research UK competition
- Horning receives Duane Roth Memorial Award
- Chang and Moore win Ehrlich-Darmstaedter Prize
- ESMO to present new award at first annual Immuno-Oncology Congress
- Jupiter Medical Center to use IBM Watson for Oncology technology
- Fox Chase, Temple earn accreditation for BMT program
- Cota, Hackensack integrate patient data into Epic EHR system
- NCCN creates Quick Guide for patients with Waldenström’s Macroglobulinemia
Drugs & Targets
- FDA approves Opdivo for urothelial carcinoma indication
- GenomeDx, Astellas work to identify genomic drivers of Xtandi response

Page 63 of 118« First «...10 20 30 40 50...59 60 61 626364 65 66 67 68...80 90 100 110...»Last »

Hundreds died over two decades as reporting requirements were ignored.